The Danger of Smoking and E-cigarettes in Brazil

Sep.02.2022
The Danger of Smoking and E-cigarettes in Brazil
Smoking is the primary cause of lung cancer in Brazil's Mato Grosso state, with e-cigarettes becoming a popular and dangerous alternative.

In the state of Mato Grosso do Sul in Brazil, there are 15.6 cases of tracheal, bronchial, and lung cancer per 100,000 males and 7.9 cases per 100,000 females, with similar ratios. According to data from the US National Cancer Institute (INCA), these types of tumors are primarily caused by smoking.


Smoking is the second leading cause of cancer in men, with only prostate cancer having a higher incidence rate. In women, it is the third leading cause, following breast and cervical cancer.


Giovanna Figaredo, a pulmonologist who works at the St. Matthew's Hospital in Cubatão, believes that in addition to traditional smoking methods such as cigarettes, cigars, and pipes, electronic cigarettes are becoming a popular and harmful trend, especially among young people.


Many individuals believe that electronic cigarettes are "healthier," but this is a myth. We must uncover the mysterious veil of this information in order to guide people away from consumption. Electronic cigarettes are banned in Brazil because they are unsafe. Many people are even unaware of what they are inhaling, the doctor explained.


This pulmonologist has warned that smoking increases the risk of more than 20 types of cancers, in addition to the most common ones such as lung cancer, bronchial cancer, and tracheal cancer. Furthermore, smoking also increases the risk of cardiovascular diseases such as heart disease and stroke. It can lead to pulmonary diseases like chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, and decreased fertility.


In regards to e-cigarettes, the long-term damage of their use is still largely unknown due to the higher consumption rates of this generation. However, there have been cases of patients with deteriorating lung conditions such as asthma. Additionally, there is EVALI (electronic cigarette or vaping product use-associated lung injury), which is an acute lung disease associated with the use of e-cigarettes," he pointed out.


Nicotine is a disease.


Doctor Giovanna Figueiredo explained that nicotine addiction is considered a disease and is classified under the International Classification of Diseases (ICD). It can lead to physical and psychological dependency.


Experts emphasize that the first step to overcoming the difficulties of quitting smoking is willpower and determination. "I usually guide people to make changes in their daily habits, such as changing the place where they usually keep their cigarettes, delaying the first cigarette of the day as much as possible, and avoiding drinks that encourage smoking, such as coffee and alcoholic beverages. After making these changes, it is important to set a date to permanently quit tobacco use.


Doctors emphasize that certain medications can assist with quitting smoking and also help control withdrawal symptoms and anxiety. They point out that seeking professional help for guidance, planning, and medication prescriptions is crucial when needed.


Statement:


This article is compiled from third-party information and is only intended for industry-related exchange and learning.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry-related communication and research purposes.


Due to limitations in the translator's ability, translated articles may not accurately reflect the original text. It is recommended to refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
Philip Morris International (PMI) has confirmed plans to bring its IQOS heated tobacco device to Argentina by the end of 2026, after the Argentine government lifted long-standing restrictions and created a regulatory framework for heated tobacco, e-cigarettes and nicotine pouches.
News
Jun.26 by 2Firsts Perspectives
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal Vape Sellers Still Use TikTok and Other Platforms to Drive Sales Despite Australia’s Ad Ban
Illegal vape sellers are still promoting nicotine products on TikTok, Instagram and YouTube despite Australia’s 2024 advertising ban, while illicit tobacco sales are increasingly moving from physical stores to online marketplaces.
Jul.15
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
U.S. technology and investigative publication WIRED has examined how nicotine analogs are emerging as a new challenge for the country’s vape regulatory framework. The article argues that after the U.S. expanded federal oversight of nicotine products in 2022, some manufacturers began using nicotine-like compounds such as 6-methyl-nicotine that may fall outside existing definitions. Researchers cited by WIRED said some nicotine analogs could be more potent than traditional nicotine, although human health impacts remain unclear. U.S. policymakers are considering broader definitions of nicotine to bring these compounds under federal oversight.
Jul.27
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
Spanish newspaper El Confidencial interviewed Fred Monteiro, Regional Director for Americas and Europe at British American Tobacco (BAT). Monteiro said BAT supports setting regulatory limits for nicotine products but opposes Spain’s proposed 0.99mg nicotine-per-pouch limit, arguing that such a restriction could affect adult smokers’ transition to alternatives. He said nicotine regulation should be based on scientific evidence and harm reduction principles. Monteiro also said smoke-free products now account for around 25% of BAT’s Americas and Europe business and nearly 30% of its Europe business
BAT
Jul.30
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Philip Morris International (PMI) has introduced the airport-exclusive limited-edition IQOS ILUMA i PRIME Skylens, the company’s first device created specifically for airport travel retail. Inspired by the world of flight and finished in metallic blue, Skylens debuted at Narita International Airport in Japan before expanding into selected airport duty-free and travel-retail channels across 13 countries in Europe, Asia, the Middle East and Africa. The product retains the existing IQOS ILUMA i PRIME platform, with differentiation centered on airport exclusivity, design and travel-retail execution rather than a new heating architecture.
PMI
Aug.19